UBS Group Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price

Vertex Pharmaceuticals (NASDAQ:VRTX) had its price objective decreased by UBS Group from $553.00 to $546.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the pharmaceutical company’s stock. UBS Group’s target price would suggest a potential upside of 33.34% from the stock’s current price.

A number of other analysts also recently weighed in on VRTX. Canaccord Genuity Group reduced their price target on shares of Vertex Pharmaceuticals from $424.00 to $411.00 and set a “hold” rating for the company in a report on Wednesday, August 6th. Scotiabank lowered their price target on Vertex Pharmaceuticals from $442.00 to $438.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 5th. Guggenheim decreased their price objective on Vertex Pharmaceuticals from $558.00 to $546.00 and set a “buy” rating on the stock in a report on Wednesday, August 6th. Evercore ISI cut their target price on Vertex Pharmaceuticals from $510.00 to $475.00 and set an “outperform” rating for the company in a research note on Thursday, September 11th. Finally, Leerink Partnrs raised Vertex Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Thursday, September 25th. One analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $489.10.

Vertex Pharmaceuticals Stock Down 1.6%

Shares of NASDAQ:VRTX opened at $409.47 on Friday. The company has a market cap of $104.98 billion, a price-to-earnings ratio of 29.27 and a beta of 0.36. The business has a 50 day moving average price of $404.55 and a 200 day moving average price of $429.56. Vertex Pharmaceuticals has a twelve month low of $362.50 and a twelve month high of $519.88.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Monday, November 3rd. The pharmaceutical company reported $4.80 EPS for the quarter, topping the consensus estimate of $4.58 by $0.22. Vertex Pharmaceuticals had a return on equity of 23.91% and a net margin of 31.86%.The company had revenue of $3.08 billion for the quarter, compared to the consensus estimate of $3.05 billion. During the same period in the previous year, the business posted $4.38 EPS. The company’s revenue for the quarter was up 11.0% on a year-over-year basis. Vertex Pharmaceuticals has set its FY 2025 guidance at EPS. Analysts anticipate that Vertex Pharmaceuticals will post 15.63 EPS for the current year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Several large investors have recently made changes to their positions in the company. Activest Wealth Management bought a new stake in Vertex Pharmaceuticals during the first quarter worth about $25,000. Clal Insurance Enterprises Holdings Ltd boosted its holdings in shares of Vertex Pharmaceuticals by 450.0% in the 1st quarter. Clal Insurance Enterprises Holdings Ltd now owns 55 shares of the pharmaceutical company’s stock worth $27,000 after acquiring an additional 45 shares in the last quarter. Access Investment Management LLC acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter worth approximately $27,000. Chesapeake Asset Management LLC grew its position in Vertex Pharmaceuticals by 110.0% during the 3rd quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after acquiring an additional 33 shares during the last quarter. Finally, Flaharty Asset Management LLC acquired a new stake in Vertex Pharmaceuticals during the 1st quarter valued at $32,000. Institutional investors own 90.96% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.